CN111205326A - 一种绿色环保的泰诺福韦制备方法 - Google Patents
一种绿色环保的泰诺福韦制备方法 Download PDFInfo
- Publication number
- CN111205326A CN111205326A CN202010090243.4A CN202010090243A CN111205326A CN 111205326 A CN111205326 A CN 111205326A CN 202010090243 A CN202010090243 A CN 202010090243A CN 111205326 A CN111205326 A CN 111205326A
- Authority
- CN
- China
- Prior art keywords
- compound
- organic solvent
- inorganic
- molar ratio
- reacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title claims abstract description 27
- 229960004556 tenofovir Drugs 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 22
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- -1 azodicarboxylic diester Chemical class 0.000 claims abstract description 10
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- GTTBQSNGUYHPNK-UHFFFAOYSA-N hydroxymethylphosphonic acid Chemical compound OCP(O)(O)=O GTTBQSNGUYHPNK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 239000012065 filter cake Substances 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 238000000967 suction filtration Methods 0.000 claims abstract description 5
- 238000001291 vacuum drying Methods 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- RWIGWWBLTJLKMK-UHFFFAOYSA-N diethoxyphosphorylmethanol Chemical compound CCOP(=O)(CO)OCC RWIGWWBLTJLKMK-UHFFFAOYSA-N 0.000 claims description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 4
- OIERWUPLBOKSRB-UHFFFAOYSA-N dimethoxyphosphorylmethanol Chemical group COP(=O)(CO)OC OIERWUPLBOKSRB-UHFFFAOYSA-N 0.000 claims description 4
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 235000011181 potassium carbonates Nutrition 0.000 claims description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 4
- UIFGGABIJBWRMG-FMQUCBEESA-N (4-chlorophenyl)methyl (ne)-n-[(4-chlorophenyl)methoxycarbonylimino]carbamate Chemical compound C1=CC(Cl)=CC=C1COC(=O)\N=N\C(=O)OCC1=CC=C(Cl)C=C1 UIFGGABIJBWRMG-FMQUCBEESA-N 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 9
- 229930024421 Adenine Natural products 0.000 abstract description 9
- 229960000643 adenine Drugs 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 5
- 229910017053 inorganic salt Inorganic materials 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000012266 salt solution Substances 0.000 abstract description 4
- 239000002351 wastewater Substances 0.000 abstract description 4
- 238000006751 Mitsunobu reaction Methods 0.000 abstract description 3
- 239000000543 intermediate Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960001627 lamivudine Drugs 0.000 description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
- QRBPRPXDUFXPGR-UHFFFAOYSA-N 2-methoxypropyl dihydrogen phosphate Chemical compound COC(C)COP(O)(O)=O QRBPRPXDUFXPGR-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 2
- 229960001355 tenofovir disoproxil Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- RUOJZAUFBMNUDX-GSVOUGTGSA-N (4r)-4-methyl-1,3-dioxolan-2-one Chemical compound C[C@@H]1COC(=O)O1 RUOJZAUFBMNUDX-GSVOUGTGSA-N 0.000 description 1
- CTKINSOISVBQLD-VKHMYHEASA-N (S)-Glycidol Chemical compound OC[C@H]1CO1 CTKINSOISVBQLD-VKHMYHEASA-N 0.000 description 1
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 description 1
- NCEGJIHRQBRVJQ-UHFFFAOYSA-N 2-amino-3-[3-[2-(phosphonomethyl)phenyl]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(C=2C(=CC=CC=2)CP(O)(O)=O)=C1 NCEGJIHRQBRVJQ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- LPEKGGXMPWTOCB-GSVOUGTGSA-N methyl (R)-lactate Chemical compound COC(=O)[C@@H](C)O LPEKGGXMPWTOCB-GSVOUGTGSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
Abstract
本发明公开了一种绿色环保的泰诺福韦制备方法,包括:将化合物I、S‑碳酸丙烯酯、无机弱碱溶于有机溶剂中,在85~120℃下反应3~6h,冷却至室温,减压浓缩体系得中间体Ⅱ;将中间体II、羟甲基膦酸二烷基酯和三烷(芳)基膦溶于有机溶剂中,在室温条件下搅拌,缓慢加入偶氮二羧酸二酯,反应20min~3h,得中间体III;向中间体III中缓慢加入无机强碱,冰浴,过滤,调节滤液pH,静置,抽滤,洗涤滤饼,减压真空干燥。本发明以S‑碳酸丙烯酯和腺嘌呤及其衍生物为起始原料,通过Mitsunobu反应的构型翻转生成PMPA,所用有机溶剂可循环使用,产生的废水以无害无机盐溶液为主,进一步处理达标排放的成本较低,绿色环保,反应易控制,安全性高,综合经济效益高。
Description
技术领域
本发明属于化学领域,涉及药物化学与废液资源化技术领域,具体涉及一种绿色环保的泰诺福韦制备方法。
背景技术
泰诺福韦(PMPA),化学名为R-9-(2-磷酸甲氧基丙基)腺嘌呤,是一款重要的抗病毒药物。1995年有学者发现PMPA可以彻底地阻止保护恒河猴的肠胃猴免疫缺陷病毒(SIV)感染。作为一种新的开环核苷酸类抗HIV感染的药物,PMBA于2001年被FDA批准上市,用于治疗艾滋病毒感染病人,在体外有极好的抗HIV和HBV的双重活性,其抗HBV的作用强于拉米夫定。在临床使用中发现其不仅对已用过拉米夫定治疗的HIV和HBV感染者适用,而且可用于治疗对拉米夫定产生耐药性的病人。由于泰诺福韦的生物利用度较低,后续又开发出富马酸复合盐和泰诺福韦酯等以PMPA为主药的前体药物,以提高其生物利用度。另外,泰诺福韦酯比大多数用来治疗HIV感染的核营类逆转录酶抑制剂产生的细胞毒性小,对患者具有良好的耐受性。
PMPA作为抗HIV药物的重要中间体,报道过多种合成方法,美国Gilead Sciences公司就泰诺福韦醋和富马酸复合盐的合成方法在专利CN1745755A中进行了报道。专利涉及的PMPA合成路线所用起始物料为(R)-乳酸甲a、D-乳酸异丁酯、(s)-缩水甘油、甲基环氧乙烷,关键手性中间体为(R)-[2-[(二异丙基)膦酰基甲氧基)丙基]腺嘌呤与(R)-9-[2-二(乙基膦酰甲氧基)丙基]腺嘌呤。国内企业常使用(R)-9-(2-磷酸甲氧基丙基)腺嘌呤或腺嘌呤为起始物料,进一步合成PMPA。中国专利CN201210552918.8和CN201410088446.4中分别公开了以R-碳酸丙烯酯和腺嘌呤及其衍生物为原料制备PMPA的技术。已报道的各类反应涉及的手性试剂往往都是R构型的,在起始物料的手性拆分过程中,S构型的原料和副产物难以得到充分的利用,降低了产品的附加值。
本发明利用构型翻转将现有合成工艺无法利用的S-碳酸丙烯酯,对PMPA的原料资源充分利用,减少废弃物排放,提高碳酸丙烯酯的综合利用效率。所用有机溶剂可循环使用,产生的废水主要以无害无机盐溶液为主,进一步处理达标排放的成本较低,处理过程更加绿色环保,反应程度更容易控制,安全性更高,提高了产品的综合经济效益。
发明内容
本发明的目的在于克服现有技术的不足,提供一种泰诺福韦的制备及其母液回收方法。
本发明上述目的通过如下技术方案实现:
一种泰诺福韦的制备方法,合成步骤及路线如下:
步骤(1),将化合物I、S-碳酸丙烯酯、无机弱碱溶于有机溶剂中,在85~120℃下反应3~6h,冷却至室温,减压浓缩体系得中间体Ⅱ;
步骤(2),将中间体II、羟甲基膦酸二烷基酯和三烷(芳)基膦溶于有机溶剂中,在室温条件下搅拌,缓慢加入偶氮二羧酸二酯,反应20min~3h,得中间体III;
步骤(3),向中间体III中缓慢加入无机强碱,冰浴,过滤,调节滤液pH,静置,抽滤,洗涤滤饼,减压真空干燥即得;
其中,A为无机弱碱;B为有机溶剂;C为偶氮二羧酸二酯;D为三烷(芳)基膦;E为无机强碱;R1为C1-C2烷基羰基;R2为C1-C2烷基;R3为C1-C2烷基。
进一步地,化合物I与无机弱碱的摩尔比为1:1~1:10;化合物I与羟甲基膦酸二烷基酯的摩尔比为1:1~1:10;化合物I与偶氮二羧酸二酯的摩尔比为1:1~1:3;化合物I与三烷(芳)基膦的摩尔比为1:1~1:3;化合物I与无机强碱的摩尔比为1:1~1:3。
进一步地,所述无机弱碱为碳酸钾、碳酸钠、碳酸氢钾、碳酸氢钠中的至少一种。
进一步地,所述有机溶剂为苯、甲苯、二甲苯、四氢呋喃、二甲基甲酰胺或二甲基乙酰胺的任一种。
进一步地,所述偶氮二酸二酯为偶氮二羧酸二乙酯、偶氮二羧酸二叔丁酯、偶氮二羧酸二异丙酯或偶氮二羧酸二对氯苄酯中的至少一种。
进一步地,所述三烷(芳)基膦为三苯膦、三丁膦或三甲膦中的至少一种。
进一步地,所述羟甲基膦酸二烷基酯为羟甲基膦酸二甲酯或羟甲基膦酸二乙酯。
进一步地,所述无机强碱为氢氧化钠、氢氧化钾、氢氧化锂中的至少一种。
进一步地,步骤(3)中于冰浴下反应1~3h,过滤,调节滤液pH至2~3,在0~10℃静置8~12h。
更进一步地,用于调节PH值的试剂为盐酸和氢氧化钠,溶液浓度均为0.5mol/L。
有益效果:
本发明以S-碳酸丙烯酯和腺嘌呤及其衍生物为起始原料,通过Mitsunobu反应的构型翻转生成PMPA,所用有机溶剂可循环使用,产生的废水主要以无害无机盐溶液为主,进一步处理达标排放的成本较低,处理过程更加绿色环保,反应程度更容易控制,安全性更高,提高了产品的综合经济效益。
具体实施方式
下面结合实施例具体介绍本发明实质性内容,但并不以此限定本发明的保护范围。
下述实施例中,室温均指常温。
实施例1:
化合物I为化合物I与碳酸钾的摩尔比为1:5;化合物I与羟甲基膦酸二甲酯的摩尔比为1:5;化合物I与偶氮二羧酸二乙酯的摩尔比为1:1.5;化合物I与三苯膦的摩尔比为1:1.5;化合物I与氢氧化钠的摩尔比为1:1.5。
具体步骤如下:
步骤(1),将化合物I(102g)、S-碳酸丙烯酯(149g)、碳酸钾(690g)水溶液溶于有机溶剂二甲基甲酰胺中,在100℃下反应4h,冷却至室温,减压浓缩体系得中间体Ⅱ;中间体Ⅱ的氢谱:1H-NMR(600MHz,DMSO-d6)δH:10.51(s,1H),8.59(s,1H),8.19(s,1H),8.05(s,1H),3.90(m,2H),3.70(d,J=8.8Hz,1H),1.16(d,J=8.8Hz,3H)。
步骤(2),将中间体II、羟甲基膦酸二甲酯(700g)和三苯膦(393.5g)溶于二甲基甲酰胺中,在室温条件下搅拌,缓慢加入偶氮二羧酸二乙酯(261g),反应1.5h,得中间体III。
步骤(3),向中间体III中缓慢加入氢氧化钠(60g)水溶液,在冰浴下反应2h,过滤,用溶液浓度均为0.5mol/L的盐酸和氢氧化钠水溶液调节滤液pH至2.5,在5℃静置10h,抽滤,洗涤滤饼,减压真空干燥即得泰诺福韦233.5g,产品纯度99.1%,得率81.3%。泰诺福韦的氢谱:1H-NMR(600MHz,D2O)δH:8.13(s,1H),8.01(s,1H),7.31(s,1H),4.21(m,3H),3.86(m,3H),3.54(d,J=6.2Hz,2H),1.16(d,J=6.2Hz,3H)。
实施例2:
化合物I为化合物I与碳酸氢钾的摩尔比为1:5;化合物I与羟甲基膦酸二乙酯的摩尔比为1:5;化合物I与偶氮二羧酸二对氯苄酯的摩尔比为1:1.5;化合物I与三甲膦的摩尔比为1:1.5;化合物I与氢氧化锂的摩尔比为1:1.5。
具体步骤如下:
步骤(1),将化合物I(149g)、S-碳酸丙烯酯(102g)、碳酸氢钾(500g)溶于有机溶剂甲苯中,在110℃下反应5h,冷却至室温,减压浓缩体系得中间体Ⅱ;中间体Ⅱ的氢谱数据;1H-NMR(600MHz,DMSO-d6)δH:10.61(s,1H),8.63(s,1H),8.03(s,1H),3.90(m,2H),3.68(d,J=8.6Hz,1H),2.14(s,3H),1.15(d,J=8.6Hz,3H)。
步骤(2),将中间体II、羟甲基膦酸二乙酯(700g)和三甲膦(114g)溶于甲苯中,在室温条件下搅拌,缓慢加入偶氮二羧酸二对氯苄酯(261g)溶液,反应2h,得中间体III。
步骤(3),向中间体III中缓慢加入无机强碱氢氧化锂(36g)溶液,冰浴下反应2h,过滤,用溶液浓度均为0.5mol/L的盐酸和氢氧化钠水溶液调节滤液pH至3,在5℃静置10h,抽滤,洗涤滤饼,减压真空干燥即得泰诺福韦213.8g,产品纯度99.4%,得率74.5%。泰诺福韦的氢谱数据同实施例1。
本发明以S-碳酸丙烯酯和腺嘌呤及其衍生物为起始原料,通过Mitsunobu反应的构型翻转生成PMPA,所用有机溶剂可循环使用,产生的废水主要以无害无机盐溶液为主,进一步处理达标排放的成本较低,处理过程更加绿色环保,反应程度更容易控制,安全性更高,提高了产品的综合经济效益。
上述实施例的作用在于具体介绍本发明的实质性内容,但本领域技术人员应当知道,不应将本发明的保护范围局限于该具体实施例。
Claims (10)
1.一种泰诺福韦的制备方法,其特征在于,合成步骤及路线如下:
步骤(1),将化合物I、S-碳酸丙烯酯、无机弱碱溶于有机溶剂中,在85~120℃下反应3~6h,冷却至室温,减压浓缩体系得中间体Ⅱ;
步骤(2),将中间体II、羟甲基膦酸二烷基酯和三烷(芳)基膦溶于有机溶剂中,在室温条件下搅拌,缓慢加入偶氮二羧酸二酯,反应20min~3h,得中间体III;
步骤(3),向中间体III中缓慢加入无机强碱,冰浴,过滤,调节滤液pH,静置,抽滤,洗涤滤饼,减压真空干燥即得;
其中,A为无机弱碱;B为有机溶剂;C为偶氮二羧酸二酯;D为三烷(芳)基膦;E为无机强碱;R1为C1-C2烷基羰基;R2为C1-C2烷基;R3为C1-C2烷基。
2.根据权利要求1所述的制备方法,其特征在于:化合物I与无机弱碱的摩尔比为1:1~1:10;化合物I与羟甲基膦酸二烷基酯的摩尔比为1:1~1:10;化合物I与偶氮二羧酸二酯的摩尔比为1:1~1:3;化合物I与三烷(芳)基膦的摩尔比为1:1~1:3;化合物I与无机强碱的摩尔比为1:1~1:3。
3.根据权利要求1所述的制备方法,其特征在于:所述无机弱碱为碳酸钾、碳酸钠、碳酸氢钾、碳酸氢钠中的至少一种。
4.根据权利要求1所述的制备方法,其特征在于:所述有机溶剂为苯、甲苯、二甲苯、四氢呋喃、二甲基甲酰胺或二甲基乙酰胺的任一种。
5.根据权利要求1所述的制备方法,其特征在于:所述偶氮二酸二酯为偶氮二羧酸二乙酯、偶氮二羧酸二叔丁酯、偶氮二羧酸二异丙酯或偶氮二羧酸二对氯苄酯中的至少一种。
6.根据权利要求1所述的制备方法,其特征在于:所述三烷(芳)基膦为三苯膦、三丁膦或三甲膦中的至少一种。
7.根据权利要求1所述的制备方法,其特征在于:所述羟甲基膦酸二烷基酯为羟甲基膦酸二甲酯或羟甲基膦酸二乙酯。
8.根据权利要求1所述的制备方法,其特征在于:所述无机强碱为氢氧化钠、氢氧化钾、氢氧化锂中的至少一种。
9.根据权利要求1所述的制备方法,其特征在于:步骤(3)中于冰浴下反应1~3h,过滤,调节滤液pH至2~3,在0~10℃静置8~12h。
10.根据权利要求9所述的制备方法,其特征在于:用于调节PH值的试剂为盐酸和氢氧化钠,溶液浓度均为0.5mol/L。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010090243.4A CN111205326B (zh) | 2020-02-13 | 2020-02-13 | 一种绿色环保的泰诺福韦制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010090243.4A CN111205326B (zh) | 2020-02-13 | 2020-02-13 | 一种绿色环保的泰诺福韦制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111205326A true CN111205326A (zh) | 2020-05-29 |
CN111205326B CN111205326B (zh) | 2020-09-22 |
Family
ID=70782761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010090243.4A Active CN111205326B (zh) | 2020-02-13 | 2020-02-13 | 一种绿色环保的泰诺福韦制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111205326B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111943982A (zh) * | 2020-08-14 | 2020-11-17 | 山东罗欣药业集团股份有限公司 | 一种抗病毒药物的合成工艺 |
CN113214322A (zh) * | 2021-04-30 | 2021-08-06 | 山东立新制药有限公司 | 替诺福韦绿色环保的制备方法 |
CN114634530A (zh) * | 2020-12-15 | 2022-06-17 | 江苏阿尔法药业有限公司 | 一种连续流微反应器合成泰诺福韦的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101648974A (zh) * | 2009-07-21 | 2010-02-17 | 广东京豪医药科技开发有限公司 | 泰诺福韦酯合成新工艺 |
CN103864847A (zh) * | 2012-12-18 | 2014-06-18 | 上海迪赛诺化学制药有限公司 | 一种制备泰诺福韦的工艺 |
CN104910209A (zh) * | 2014-03-11 | 2015-09-16 | 上海创诺医药集团有限公司 | 一种制备泰诺福韦的方法 |
US20170233419A1 (en) * | 2011-12-22 | 2017-08-17 | Geron Corporation | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors |
-
2020
- 2020-02-13 CN CN202010090243.4A patent/CN111205326B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101648974A (zh) * | 2009-07-21 | 2010-02-17 | 广东京豪医药科技开发有限公司 | 泰诺福韦酯合成新工艺 |
US20170233419A1 (en) * | 2011-12-22 | 2017-08-17 | Geron Corporation | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors |
CN103864847A (zh) * | 2012-12-18 | 2014-06-18 | 上海迪赛诺化学制药有限公司 | 一种制备泰诺福韦的工艺 |
CN104910209A (zh) * | 2014-03-11 | 2015-09-16 | 上海创诺医药集团有限公司 | 一种制备泰诺福韦的方法 |
Non-Patent Citations (4)
Title |
---|
ATUL MANVAR等: ""Diversity oriented efficient access of trisubstituted purines via sequential regioselective Mitsunobu coupling and SNAr based C6 functionalizations"", 《TETRAHEDRON》 * |
KAREL POMEISL等: ""Utilization of 1,3-Dioxolanes in the Synthesis ofα-branched Alkyl and Aryl 9-[2-(Phosphonomethoxy)Ethyl]Purines and Study of the Influence of α-branched Substitution for Potential Biological Activity"", 《NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS》 * |
WEI CHEN等: ""AN IMPROVED SYNTHESIS OF 9-[2-(DIETHOXYPHOSPHONOMETHOXY)ETHYL]ADENINE AND ITS ANALOGUES WITH OTHER PURINE BASES UTILIZING THE MITSUNOBU REACTION"", 《NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS》 * |
WEI CHEN等: ""INTRODUCTION OF α-FLUOROPHOSPHONOMETHYL ETHER FUNCTIONALITY AND ITS APPLICATION TO THE SYNTHESIS OF FLUORINATED ACYCLIC PHOSPHONATE NUCLEOSIDES"", 《TETRAHEDRON LETTERS》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111943982A (zh) * | 2020-08-14 | 2020-11-17 | 山东罗欣药业集团股份有限公司 | 一种抗病毒药物的合成工艺 |
CN111943982B (zh) * | 2020-08-14 | 2023-10-10 | 山东罗欣药业集团股份有限公司 | 一种抗病毒药物的合成工艺 |
CN114634530A (zh) * | 2020-12-15 | 2022-06-17 | 江苏阿尔法药业有限公司 | 一种连续流微反应器合成泰诺福韦的方法 |
CN114634530B (zh) * | 2020-12-15 | 2023-11-03 | 江苏阿尔法药业股份有限公司 | 一种连续流微反应器合成泰诺福韦的方法 |
CN113214322A (zh) * | 2021-04-30 | 2021-08-06 | 山东立新制药有限公司 | 替诺福韦绿色环保的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111205326B (zh) | 2020-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111205326B (zh) | 一种绿色环保的泰诺福韦制备方法 | |
CN103374038B (zh) | 一种抗病毒药物的制备方法 | |
CN104817593B (zh) | 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺 | |
CN103360425A (zh) | 替诺福韦酯及其富马酸盐的合成方法 | |
CN104610360A (zh) | 一种富马酸替诺福韦二吡呋酯的制备方法 | |
CN101648978A (zh) | 一种高纯度的六苯氧基环三磷腈的制造方法 | |
CN101418017B (zh) | (r)-9-(2-磷酸甲氧基丙基)腺嘌呤的合成方法 | |
CN104628773A (zh) | (r)-9-[2-(磷酰苯酚基甲氧基)丙基]腺嘌呤的制备方法 | |
CN104672281A (zh) | 一种制备高纯富马酸替诺福韦二吡呋酯的方法 | |
CN102321086B (zh) | 一种腺嘌呤的合成方法 | |
CN110452269B (zh) | 一种利用微反应器制备替诺福韦的方法 | |
CN106632484A (zh) | 一种替诺福韦艾拉酚胺的制备方法 | |
CN105622671A (zh) | 一种可工业化大生产富马酸替诺福韦二吡呋酯的制备方法 | |
CN106674281B (zh) | 一种瑞舒伐他汀中间体化合物、制备方法及其用途 | |
CN104230987B (zh) | 一种[1-卤代-(2-丙氧基)]-甲基膦酸类化合物及其制备和应用 | |
CN104341452A (zh) | 富马酸替诺福韦酯杂质的制备方法 | |
CN108794479A (zh) | 一种4-氯吡咯并嘧啶的合成方法 | |
CN100526321C (zh) | 一种合成阿德福韦的方法 | |
CN102899367B (zh) | 一种生物法和化学法结合合成泰诺福韦的方法 | |
CN104844459B (zh) | 一种氯甲基异丙基碳酸酯的制备方法 | |
CN111303045A (zh) | 2-乙氧基-4,6-二氟嘧啶的生产工艺 | |
CN114751909B (zh) | 一种瑞博西尼中间体的制备方法 | |
CN114621228B (zh) | 一种2-氨基-6-氯嘌呤的制备方法 | |
CN113214322B (zh) | 替诺福韦绿色环保的制备方法 | |
CN111943982B (zh) | 一种抗病毒药物的合成工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231024 Address after: Rooms 1503 and 1504, 15th floor, Building F, Life Science Park, No. 22 Tiansheng Road, Jiangbei New District, Nanjing, Jiangsu Province, 210000 Patentee after: Nanjing Dao'er Medical Research Institute Co.,Ltd. Address before: Room 1501-1511, Building J, Zhengda Himalaya Center, No. 9 Liuchao Road, Yuhuatai District, Nanjing City, Jiangsu Province, 210012 Patentee before: NANJING DARRA PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |